Clinical Trial

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-30; most recent amendment 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT07107256
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 246 participants
Start Date 2025-09-25
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-16